Addex Therapeutics Ltd
ADXN
$7.29
$0.41526.04%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 146.34% | 133.19% | 30.00% | 46.13% | 46.02% |
| Total Depreciation and Amortization | 215.95% | 33.68% | -59.85% | -70.66% | -74.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -553.42% | -535.26% | -21.25% | -38.50% | -23.91% |
| Change in Net Operating Assets | 98.54% | 69.96% | 358.47% | 104.83% | -223.65% |
| Cash from Operations | 40.81% | 23.99% | 39.40% | 48.63% | 34.24% |
| Capital Expenditure | 53.97% | 63.93% | -51.52% | -1,183.33% | 76.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 139,383.78% | -- | -- | -100.00% |
| Cash from Investing | 81,888.89% | 215,045.83% | -1,350.00% | -348.39% | 73.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 49.59% | 24.05% | 28.29% | 2.19% | 5.19% |
| Issuance of Common Stock | -88.17% | -93.18% | -50.22% | 39.54% | -56.81% |
| Repurchase of Common Stock | 61.44% | 60.95% | 68.04% | 83.71% | 88.77% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -101.87% | -102.63% | 31.98% | 61.35% | -54.57% |
| Cash from Financing | -98.98% | -101.51% | -3.84% | 83.31% | -53.20% |
| Foreign Exchange rate Adjustments | 60.60% | 71.94% | -12.92% | -95.21% | -127.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.24% | -136.13% | 53.17% | 75.81% | -14.85% |
